133 related articles for article (PubMed ID: 17928740)
41. [Molecular mechanisms of the hepatitis C virus, potential therapeutic targets].
Rivas-Estilla AM; Panduro A
Rev Invest Clin; 2003; 55(1):51-64. PubMed ID: 12708164
[TBL] [Abstract][Full Text] [Related]
42. An overview: in vitro models of HCV replication in different cell cultures.
Tariq H; Manzoor S; Parvaiz F; Javed F; Fatima K; Qadri I
Infect Genet Evol; 2012 Jan; 12(1):13-20. PubMed ID: 22061839
[TBL] [Abstract][Full Text] [Related]
43. Establishment of infectious HCV virion-producing cells with newly designed full-genome replicon RNA.
Arai M; Suzuki H; Tobita Y; Takagi A; Okamoto K; Ohta A; Sudoh M; Kohara M
Arch Virol; 2011 Feb; 156(2):295-304. PubMed ID: 21246385
[TBL] [Abstract][Full Text] [Related]
44. Cell culture and infection system for hepatitis C virus.
Kato T; Date T; Murayama A; Morikawa K; Akazawa D; Wakita T
Nat Protoc; 2006; 1(5):2334-9. PubMed ID: 17406476
[TBL] [Abstract][Full Text] [Related]
45. Generation of a recombinant reporter hepatitis C virus useful for the analyses of virus entry, intra-cellular replication and virion production.
Kamada K; Shoji I; Deng L; Aoki C; Ratnoglik SL; Wakita T; Hotta H
Microbes Infect; 2012 Jan; 14(1):69-78. PubMed ID: 21917232
[TBL] [Abstract][Full Text] [Related]
46. S-adenosyl-L-methionine modifies antioxidant-enzymes, glutathione-biosynthesis and methionine adenosyltransferases-1/2 in hepatitis C virus-expressing cells.
Lozano-Sepulveda SA; Bautista-Osorio E; Merino-Mascorro JA; Varela-Rey M; Muñoz-Espinosa LE; Cordero-Perez P; Martinez-Chantar ML; Rivas-Estilla AM
World J Gastroenterol; 2016 Apr; 22(14):3746-57. PubMed ID: 27076759
[TBL] [Abstract][Full Text] [Related]
47. [Evaluation and application of natural products for viral infections].
Hayashi K; Hayashi T; Lee JB
Yakugaku Zasshi; 2010 Feb; 130(2):171-6. PubMed ID: 20118639
[TBL] [Abstract][Full Text] [Related]
48. New efficient replication system with hepatitis C virus genome derived from a patient with acute hepatitis C.
Mori K; Abe K; Dansako H; Ariumi Y; Ikeda M; Kato N
Biochem Biophys Res Commun; 2008 Jun; 371(1):104-9. PubMed ID: 18406345
[TBL] [Abstract][Full Text] [Related]
49. Pathogenesis, diagnosis and management of hepatitis C.
Boyer N; Marcellin P
J Hepatol; 2000; 32(1 Suppl):98-112. PubMed ID: 10728798
[TBL] [Abstract][Full Text] [Related]
50. Molecular biology of hepatitis C virus.
Suzuki T; Aizaki H; Murakami K; Shoji I; Wakita T
J Gastroenterol; 2007 Jun; 42(6):411-23. PubMed ID: 17671755
[TBL] [Abstract][Full Text] [Related]
51. Detection of anti-hepatitis C virus effects of interferon and ribavirin by a sensitive replicon system.
Kato T; Date T; Miyamoto M; Sugiyama M; Tanaka Y; Orito E; Ohno T; Sugihara K; Hasegawa I; Fujiwara K; Ito K; Ozasa A; Mizokami M; Wakita T
J Clin Microbiol; 2005 Nov; 43(11):5679-84. PubMed ID: 16272504
[TBL] [Abstract][Full Text] [Related]
52. [The molecular biology of hepatitis C virus].
Koutsoudakis G; Forns X; Pérez-Del-Pulgar S
Gastroenterol Hepatol; 2013 Apr; 36(4):280-93. PubMed ID: 23490024
[TBL] [Abstract][Full Text] [Related]
53. [Molecular virology of hepatitis C].
Moradpour D; Brass V; Gosert R; Wölk B; Blum HE
Praxis (Bern 1994); 2002 Dec; 91(51-52):2247-53. PubMed ID: 12564041
[TBL] [Abstract][Full Text] [Related]
54. Benzothiazepinecarboxamides: Novel hepatitis C virus inhibitors that interfere with viral entry and the generation of infectious virions.
Kim HY; Kong S; Oh S; Yang J; Jo E; Ko Y; Kim SH; Hwang JY; Song R; Windisch MP
Antiviral Res; 2016 May; 129():39-46. PubMed ID: 26850830
[TBL] [Abstract][Full Text] [Related]
55. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
[TBL] [Abstract][Full Text] [Related]
56. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.
Gottwein JM; Scheel TK; Jensen TB; Lademann JB; Prentoe JC; Knudsen ML; Hoegh AM; Bukh J
Hepatology; 2009 Feb; 49(2):364-77. PubMed ID: 19148942
[TBL] [Abstract][Full Text] [Related]
57. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
58. SELECTIVE INHIBITION OF HEPATITIS C VIRUS REPLICATION BY ALPHA-ZAM, A
Oyero OG; Toyama M; Mitsuhiro N; Onifade AA; Hidaka A; Okamoto M; Baba M
Afr J Tradit Complement Altern Med; 2016; 13(6):144-148. PubMed ID: 28480371
[TBL] [Abstract][Full Text] [Related]
59. Development and characterization of a recombinant cDNA-based hepatitis C virus system.
Ndjomou J; Liu Y; O'Malley J; Ericsson M; He JJ
Biochem Biophys Res Commun; 2007 Jul; 359(1):57-62. PubMed ID: 17531196
[TBL] [Abstract][Full Text] [Related]
60. Permissiveness of human hepatocellular carcinoma cell lines for hepatitis C virus entry and replication.
Coto-Llerena M; Koutsoudakis G; Boix L; López-Oliva JM; Caro-Pérez N; Fernández-Carrillo C; González P; Gastaminza P; Bruix J; Forns X; Pérez-Del-Pulgar S
Virus Res; 2017 Aug; 240():35-46. PubMed ID: 28751105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
